NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas
Abstract The tumor suppressor gene neurofibromin 1 (NF1) is a major regulator of the RAS‐MAPK pathway. NF1 mutations occur in lung cancer but were not extensively explored. We hypothesized that NF1‐mutated tumors could define a specific population with a distinct clinical and molecular profile. We p...
Main Authors: | Camille Tlemsani, Nicolas Pécuchet, Aurelia Gruber, Ingrid Laurendeau, Claire Danel, Marc Riquet, Françoise Le Pimpec‐Barthes, Elizabeth Fabre, Audrey Mansuet‐Lupo, Diane Damotte, Marco Alifano, Armelle Luscan, Benoit Rousseau, Dominique Vidaud, Jennifer Varin, Beatrice Parfait, Ivan Bieche, Karen Leroy, Pierre Laurent‐Puig, Benoit Terris, Helene Blons, Michel Vidaud, Eric Pasmant |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2175 |
Similar Items
-
Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR
by: Wolkenstein Pierre, et al.
Published: (2004-07-01) -
Prenatal diagnosis for neurofibromatosis type 1 and the pitfalls of germline mosaics
by: Laurence Pacot, et al.
Published: (2024-09-01) -
Mat-CHN software for drug substance titrations in discovery and development
by: Lionel Vidaud
Published: (2018-06-01) -
Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data
by: Sabbagh Audrey, et al.
Published: (2009-12-01) -
Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma
by: Jeremy Slomka, et al.
Published: (2024-01-01)